000661 长春高新
已收盘 03-16 15:00:00
资讯
新帖
简况
“春风送岗”，长春高新区举办2026年春季人才招聘会
长春广播电视台 · 13:31
“春风送岗”，长春高新区举办2026年春季人才招聘会
长春高新最新公告：子公司GenSci128片获美国FDA孤儿药资格认定
证券之星 · 03-10
长春高新最新公告：子公司GenSci128片获美国FDA孤儿药资格认定
本周六长春高新区有大型招聘会
长春市政府网站 · 03-10
本周六长春高新区有大型招聘会
长春高新：公司会严格执行薪酬管理办法
证券之星 · 03-06
长春高新：公司会严格执行薪酬管理办法
长春高新：聚焦研发创新与临床价值
证券之星 · 03-06
长春高新：聚焦研发创新与临床价值
长春高新(000661.SZ)：GenSci161注射液境内生产药品注册临床试验申请获得受理
智通财经 · 03-02
长春高新(000661.SZ)：GenSci161注射液境内生产药品注册临床试验申请获得受理
长春高新儿童小阴茎新药获批临床，股价两日涨超12%
21世纪经济报道 · 02-26
长春高新儿童小阴茎新药获批临床，股价两日涨超12%
异动快报：长春高新（000661）2月25日14点45分触及涨停板
证券之星 · 02-25
异动快报：长春高新（000661）2月25日14点45分触及涨停板
长春高新(000661.SZ)：GenSci141软膏境内生产药品注册临床试验申请获批准
智通财经 · 02-24
长春高新(000661.SZ)：GenSci141软膏境内生产药品注册临床试验申请获批准
长春高新：屋尘螨变应原舌下片已获欧美批准
证券之星 · 02-13
长春高新：屋尘螨变应原舌下片已获欧美批准
长春高新：公司研发投入及产出是基于长期战略布局的系统性成果
证券之星 · 02-13
长春高新：公司研发投入及产出是基于长期战略布局的系统性成果
长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准
证券之星 · 02-13
长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准
长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛
新浪证券 · 02-13
长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛
长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准
智通财经 · 02-09
长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准
长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入
证券之星 · 02-06
长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入
长春高新：医药生物行业也是典型的科技 + 民生双属性行业
证券之星 · 02-06
长春高新：医药生物行业也是典型的科技 + 民生双属性行业
2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股
证券之星 · 02-02
2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股
长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理
智通财经 · 02-02
长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理
医保数据发布再升级；多家药企发布业绩预告
21世纪经济报道 · 02-02
医保数据发布再升级；多家药企发布业绩预告
长春高新：预计2025年全年每股收益盈利:0.37元至0.55元
证券之星 · 01-30
长春高新：预计2025年全年每股收益盈利:0.37元至0.55元
加载更多
公司概况
公司名称：
长春高新技术产业(集团)股份有限公司
所属行业：
医药制造业
上市日期：
1996-12-18
主营业务：
长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。
发行价格：
8.80
{"stockData":{"symbol":"000661","market":"SZ","secType":"STK","nameCN":"长春高新","latestPrice":91.24,"timestamp":1773644634000,"preClose":90,"halted":0,"volume":4299935,"delay":0,"changeRate":0.0138,"floatShares":400000000,"shares":408000000,"eps":2.351,"marketStatus":"已收盘","change":1.24,"latestTime":"03-16 15:00:00","open":89.9,"high":91.53,"low":89.61,"amount":390000000,"amplitude":0.0213,"askPrice":91.24,"askSize":11,"bidPrice":91.23,"bidSize":82,"shortable":0,"etf":0,"ttmEps":2.351,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1773711000000},"marketStatusCode":5,"adr":0,"adjPreClose":90,"symbolType":"stock","openAndCloseTimeList":[[1773624600000,1773631800000],[1773637200000,1773644400000]],"highLimit":99,"lowLimit":81,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":407937529,"isCdr":false,"pbRate":1.6,"roa":"--","peRate":38.809017,"roe":"5.03%","epsLYR":6.42,"committee":0.458824,"marketValue":37220000000,"turnoverRate":0.0108,"status":0,"floatMarketCap":36461000000},"requestUrl":"/m/hq/s/000661","defaultTab":"news","newsList":[{"id":"2619007439","title":"“春风送岗”，长春高新区举办2026年春季人才招聘会","url":"https://stock-news.laohu8.com/highlight/detail?id=2619007439","media":"长春广播电视台","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619007439?lang=zh_cn&edition=full","pubTime":"2026-03-16 13:31","pubTimestamp":1773639060,"startTime":"0","endTime":"0","summary":"3月14日，长春高新区“才聚高新 创享未来”2026年春季人才招聘会在中商·世界里购物中心举行。作为长春新区产业发展与科技创新的核心引擎，长春高新区始终坚持“发展是第一要务，人才是第一资源”的理念。本次春季招聘大会，既是高新区落实“人才强区”战略、服务企业、稳定就业的务实之举，也是构建人才与企业直接对话、助力人才扎根高新、建功立业的关键平台。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/roll/2026-03-16/doc-inhreeev8883258.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661","BK0046","BK0188","BK0075","BK0028","BK0057","BK0239"],"gpt_icon":0},{"id":"2618939437","title":"长春高新最新公告：子公司GenSci128片获美国FDA孤儿药资格认定","url":"https://stock-news.laohu8.com/highlight/detail?id=2618939437","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618939437?lang=zh_cn&edition=full","pubTime":"2026-03-10 18:10","pubTimestamp":1773137428,"startTime":"0","endTime":"0","summary":"长春高新(000661.SZ)公告称，公司子公司金赛药业收到美国FDA通知，GenSci128片获孤儿药资格认定，用于治疗胰腺癌。该药品为治疗用化药1类新药，针对TP53 Y220C突变的选择性重激活剂。获得孤儿药资格认定有助于GenSci128片在美国的后续研发和审评过程中获得政策支持，包括临床试验费用的税收抵免、免除新药申请费等。但医药产品具有高风险、高附加值特点，临床试验进程存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031000030594.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","000661","BK0075","BK0028","BK0057","BK0046"],"gpt_icon":0},{"id":"2618836869","title":"本周六长春高新区有大型招聘会","url":"https://stock-news.laohu8.com/highlight/detail?id=2618836869","media":"长春市政府网站","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618836869?lang=zh_cn&edition=full","pubTime":"2026-03-10 12:34","pubTimestamp":1773117240,"startTime":"0","endTime":"0","summary":"转自：长春发布@正在找工作的你金三银四招聘季，春风行动送岗来！不想奔波找工作？不想盲目海投无回应？想要家门口的优质岗、有保障的好工作？别犹豫，看这里！👇👇👇长春高新区2026年春季人才招聘大会重磅来袭！100+优质企业！3000+空缺岗位！企业直招、实时选岗、政策解读、就业指导...助你在这个春天，斩获心仪offer，✨ 奔赴美好前程！✨来 源：长春高新人才编 辑：刘素娜\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-03-10/doc-inhqnrqu0111881.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","000661","BK0028","BK0075","BK0046","BK0057","BK0188"],"gpt_icon":0},{"id":"2617689175","title":"长春高新：公司会严格执行薪酬管理办法","url":"https://stock-news.laohu8.com/highlight/detail?id=2617689175","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617689175?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:39","pubTimestamp":1772789954,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)03月06日在投资者关系平台上答复投资者关心的问题。投资者提问：公司多次回复称“深化费用精细化管控” ，但从2025年业绩预告来看，费用端依然严重侵蚀利润。投资者看到的是公司赚钱管理层花，一分不留给股东 。请问面对濒临亏损的局面，2026年管理层工资薪酬是否愿意与净利润增幅挂钩，与中小股东共渡难关？长春高新回复：您好，公司会严格执行薪酬管理办法，实现薪酬分配与公司业绩考核评价的有机结合，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028812.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0057","BK0188","BK0046","000661","BK0028","BK0239"],"gpt_icon":0},{"id":"2617686299","title":"长春高新：聚焦研发创新与临床价值","url":"https://stock-news.laohu8.com/highlight/detail?id=2617686299","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617686299?lang=zh_cn&edition=full","pubTime":"2026-03-06 17:30","pubTimestamp":1772789437,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新03月06日在投资者关系平台上答复投资者关心的问题。具体新产品及在研产品情况可参见公司相关公告，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030600028511.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","000661","BK0075","BK0028","BK0057","BK0046","BK0239"],"gpt_icon":0},{"id":"2616838438","title":"长春高新(000661.SZ)：GenSci161注射液境内生产药品注册临床试验申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2616838438","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616838438?lang=zh_cn&edition=full","pubTime":"2026-03-02 16:38","pubTimestamp":1772440714,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)发布公告，近日，公司控股子公司——长春金赛药业有限责任公司(以下简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GenSci161注射液的境内生产药品注册临床试验申请获得受理。GenSci161注射液可同时靶向关键促炎细胞因子白细胞介素-1(IL-1)的两种亚型——IL-1α和IL-1β，有望抑制下游炎症信号通路的激活，为中重度患者提供新的长期系统治疗选择。目前，GenSci161注射液已在临床前动物模型中表现出良好的疗效，展现出治疗子宫内膜异位症及化脓性汗腺炎的潜力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1408972.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：GenSci161注射液境内生产药品注册临床试验申请获得受理","news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0075","BK0188","BK0239","BK0046","BK0028","BK0057"],"gpt_icon":0},{"id":"2614703094","title":"长春高新儿童小阴茎新药获批临床，股价两日涨超12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614703094","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614703094?lang=zh_cn&edition=full","pubTime":"2026-02-26 15:04","pubTimestamp":1772089440,"startTime":"0","endTime":"0","summary":" 2月25日，长春高新以涨停收盘，报97.26元/股，收获2026年开年以来首个涨停；2月26日公司股价持续上行，截至14：30左右，报100元/股，涨幅2.82%，总市值达408亿元，股价两日累计涨超12%。 据财联社报道，长春高新证券部公司人士回应称，该产品当前仅获批开展此前公告所述临床试验，适应症需严格按照批件执行。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-26/doc-inhpcqkk7304859.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/marketresearch/2026-02-26/doc-inhpcqkk7304859.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["000661","BK0075","BK0188","BK0239","BK0046","BK0028","BK0057"],"gpt_icon":0},{"id":"2614708896","title":"异动快报：长春高新（000661）2月25日14点45分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2614708896","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614708896?lang=zh_cn&edition=full","pubTime":"2026-02-25 14:45","pubTimestamp":1772001922,"startTime":"0","endTime":"0","summary":"证券之星2月25日盘中消息，14点45分长春高新触及涨停板。其所属行业生物制品目前上涨。领涨股为三生国健。该股为疫苗，阿尔茨海默病，振兴东北概念热股，当日疫苗概念上涨1.48%，阿尔茨海默病概念上涨1.33%，振兴东北概念上涨1.28%。2月24日的资金流向数据方面，主力资金净流出336.47万元，占总成交额1.23%，游资资金净流入573.18万元，占总成交额2.1%，散户资金净流出236.72万元，占总成交额0.87%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500018219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0239","BK0028","BK0188","BK0075","BK0046","BK0057"],"gpt_icon":0},{"id":"2613679465","title":"长春高新(000661.SZ)：GenSci141软膏境内生产药品注册临床试验申请获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2613679465","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613679465?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:53","pubTimestamp":1771926838,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司子公司——长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业GenSci141软膏境内生产药品注册临床试验申请获得批准。该药品适应症：用于改善因高促性腺激素性性腺功能减退症、5α-还原酶2缺乏症、雄激素合成减少的先天性肾上腺皮质增生症、特发性的原因导致的儿童小阴茎。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1406733.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：GenSci141软膏境内生产药品注册临床试验申请获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0239","BK0028","BK0046","BK0188","BK0057","BK0075"],"gpt_icon":0},{"id":"2611132191","title":"长春高新：屋尘螨变应原舌下片已获欧美批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611132191","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611132191?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:57","pubTimestamp":1770973027,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月13日在投资者关系平台上答复投资者关心的问题。其他疾病事项建议咨询专业的医护人员，谢谢！","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300026422.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","BK0075","000661","BK0046","BK0239","BK0057","BK0028"],"gpt_icon":0},{"id":"2611131719","title":"长春高新：公司研发投入及产出是基于长期战略布局的系统性成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2611131719","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611131719?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:27","pubTimestamp":1770971228,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月13日在投资者关系平台上答复投资者关心的问题。请问贵公司的研发费用到底有多少真实投入到研发工作中？","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300025354.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0046","BK0239","BK0057","BK0028","BK0188","000661"],"gpt_icon":0},{"id":"2611813172","title":"长春高新：GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2611813172","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611813172?lang=zh_cn&edition=full","pubTime":"2026-02-13 16:27","pubTimestamp":1770971227,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新(000661)02月13日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司有几个项目在美国已经获批临床了的，目前分别进展到什么阶段了？长春高新回复：您好，近年来公司GenSci122片、GS1-144、GenSci120注射液、GenSci128片等产品陆续获得美国临床批准，相关产品会综合国内同产品研发进度及临床进展表现等，未来合理安排推进海外研发相关工作，谢谢！以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021300025351.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0057","000661","BK0046","BK0188","BK0239","BK0075"],"gpt_icon":0},{"id":"2611213567","title":"长春高新业绩“雪崩”：生长激素神话终结后的转型阵痛","url":"https://stock-news.laohu8.com/highlight/detail?id=2611213567","media":"新浪证券","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611213567?lang=zh_cn&edition=full","pubTime":"2026-02-13 15:12","pubTimestamp":1770966720,"startTime":"0","endTime":"0","summary":"近日，“东北药茅”长春高新发布2025年度业绩预告，归母净利润预计仅为1.50亿元至2.20亿元，同比暴跌逾九成，创下近二十年最差表现。尤其令市场震惊的是第四季度单季亏损接近10亿元，同比增亏约360%至390%，呈现出罕见的业绩“断崖”。 曾经依赖生长激素这一“利润引擎”高歌猛进的长春高新，如今正面临产品降价、竞争加剧、新增长点尚未成型的多重压力。 长春高新业绩骤降的核心，直接指向其长期以来高度依赖的生长激素业务。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/aigcy/2026-02-13/doc-inhmscxf6010928.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","BK0075","000661","BK0188","BK0057","BK0046","BK0028"],"gpt_icon":0},{"id":"2610655243","title":"长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2610655243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610655243?lang=zh_cn&edition=full","pubTime":"2026-02-09 21:55","pubTimestamp":1770645339,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新 发布公告，近日，公司子公司——长春金赛药业有限责任公司收到国家药品监督管理局核准签发的《药物临床试验批准通知书》，金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准。注射用GenSci136是金赛药业自主研发的一款治疗用生物制品1类药物，拟用于治疗免疫球蛋白A肾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403367.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：金赛药业注射用GenSci136境内生产药品注册临床试验申请获得批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["000661","BK0046","BK0075","BK0028","BK0057","BK0239","BK0188"],"gpt_icon":0},{"id":"2609507475","title":"长春高新：公司相关销售费用系核心产品市场维护、新品商业化落地等经营发展的阶段性必要投入","url":"https://stock-news.laohu8.com/highlight/detail?id=2609507475","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609507475?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:51","pubTimestamp":1770364267,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：销售费用50亿,公司净利润不到2亿。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600022709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","000661","BK0057","BK0188","BK0028","BK0075","BK0046"],"gpt_icon":0},{"id":"2609572625","title":"长春高新：医药生物行业也是典型的科技 + 民生双属性行业","url":"https://stock-news.laohu8.com/highlight/detail?id=2609572625","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609572625?lang=zh_cn&edition=full","pubTime":"2026-02-06 15:30","pubTimestamp":1770363030,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新02月06日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司董秘，现在国家大力提倡科技，我们医药生物类算不算科技公司，是不是半导体类的面子工程比医药类的民生福祉更重要，公司市值已经跌了80%且还在不断下跌，有什么办法能让市场重视一下我们医药公司？","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020600020490.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["000661","BK0057","BK0188","BK0239","BK0046","BK0028","163118","BK0075","000808.SH"],"gpt_icon":0},{"id":"2608851131","title":"2月2日长春高新跌6.14%，招商国证生物医药指数(LOF)C基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2608851131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608851131?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:47","pubTimestamp":1770022049,"startTime":"0","endTime":"0","summary":"证券之星消息，2月2日长春高新跌6.14%创60日新低，收盘报90.01元，换手率2.73%，成交量10.9万手，成交额9.9亿元。重仓长春高新的前十大公募基金请见下表：该股最近90天内共有2家机构给出评级，买入评级2家。根据2025基金年报公募基金重仓股数据，重仓该股的公募基金共31家，其中持有数量最多的公募基金为招商基金的招商国证生物医药指数C。招商国证生物医药指数C目前规模为14.39亿元，最新净值0.4035，较上一交易日下跌0.98%，近一年上涨12.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020200023582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0028","161726","000661","BK0075","399441","BK0057","BK0046"],"gpt_icon":0},{"id":"2608530851","title":"长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2608530851","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608530851?lang=zh_cn&edition=full","pubTime":"2026-02-02 16:41","pubTimestamp":1770021699,"startTime":"0","endTime":"0","summary":"智通财经APP讯，长春高新(000661.SZ)公告，公司控股子公司长春金赛药业有限责任公司(简称“金赛药业”)收到国家药品监督管理局核准签发的《受理通知书》，金赛药业GS3-007a干混悬剂的境内生产药品注册临床试验申请获得受理。公告显示，GS3-007a干混悬剂是金赛药业自主研发的口服小分子生长激素促分泌药物，注册分类为化药1类，拟用于特发性身材矮小(ISS)的治疗。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400557.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"长春高新(000661.SZ)：GS3-007a干混悬剂境内生产药品注册临床试验申请获受理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0075","000661","BK0188","BK0057","BK0046","BK0028"],"gpt_icon":0},{"id":"2608887409","title":"医保数据发布再升级；多家药企发布业绩预告","url":"https://stock-news.laohu8.com/highlight/detail?id=2608887409","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608887409?lang=zh_cn&edition=full","pubTime":"2026-02-02 08:04","pubTimestamp":1769990666,"startTime":"0","endTime":"0","summary":"政策动向医保数据发布再升级2月1日，国家医保局官微发文称，医保数据工作组是医保部门的一项创新性工作。数据发布活动组织一年多以来，各地发布内容不断丰富，发布形式更加多样，一些地方基于按病种付费改革开展病种专题分析，为疾病诊疗资源消耗“画像”，为医疗机构提供更加具体、好用的管理工具。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602023638025174.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602023638025174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","LU2488822045.USD","LU1223083913.SGD","LU1328615791.USD","BK4017","LU1223082196.USD","LU2328871848.SGD","LU1064131003.USD","BK0196","BK0046","BK1583","300122","000661","BK0077","688331","BK0239","BK0057","LU2580892862.HKD","CDE","BK1574","BK0028","09995","688506","LU2580892789.USD","BK0075","LU1969619763.USD","LU2148510915.USD","LU1223082519.USD","LU1064130708.USD","BK0188"],"gpt_icon":0},{"id":"2607010377","title":"长春高新：预计2025年全年每股收益盈利:0.37元至0.55元","url":"https://stock-news.laohu8.com/highlight/detail?id=2607010377","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607010377?lang=zh_cn&edition=full","pubTime":"2026-01-30 20:07","pubTimestamp":1769774848,"startTime":"0","endTime":"0","summary":"证券之星消息，长春高新发布业绩预告，预计2025年全年每股收益盈利:0.37元至0.55元。根据相关会计政策要求及被授权方实际付款节点，授权合作相关款项在 2025 年度内尚未确认，因此未对报告期内业绩产生影响。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000041113.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0075","BK0188","BK0057","000661","BK0028","BK0046","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1773651199334,"stockEarnings":[{"period":"1week","weight":-0.0102},{"period":"1month","weight":0.0217},{"period":"3month","weight":-0.039},{"period":"6month","weight":-0.284},{"period":"1year","weight":-0.0527},{"period":"ytd","weight":-0.0276}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":-0.0088},{"period":"3month","weight":0.053},{"period":"6month","weight":0.0581},{"period":"1year","weight":0.2193},{"period":"ytd","weight":0.0319}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"长春高新技术产业(集团)股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"104055人(较上一季度减少4.63%)","perCapita":"3840股","listingDate":"1996-12-18","address":"吉林省长春市朝阳区高新区海容酒店及海茵广场写字楼B座2708室","registeredCapital":"40793万元","survey":" 长春高新技术产业(集团)股份有限公司的主营业务是生物制药及中成药的研发、生产和销售，辅以房地产开发等业务。公司的主要产品是注射用人生长激素、重组人生长激素注射液、聚乙二醇重组人生长激素注射液、营养保健产品、体重控制产品、电子注射笔、骨龄及生长发育检测设备、赛优姿系列产品、盐酸托莫西汀胶囊、注射用重组人促卵泡激素、醋酸曲普瑞林注射液、利丙双卡因乳膏、醋酸甲地孕酮口服混悬液、口腔凝胶。","listedPrice":8.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"长春高新,000661,长春高新股票,长春高新股票老虎,长春高新股票老虎国际,长春高新行情,长春高新股票行情,长春高新股价,长春高新股市,长春高新股票价格,长春高新股票交易,长春高新股票购买,长春高新股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"长春高新(000661)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供长春高新(000661)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}